IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

SANOFI-AVENTIS U.S. LLC and SANOFI MATURE IP,	)	
Plaintiffs,	)	
v.	)	C.A. No. 20-761 (RGA)
MYLAN LABORATORIES LIMITED,	)	
Defendant.	)	

PLAINTIFFS' FIRST AMENDED COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs Sanofi-Aventis U.S. LLC (hereinafter "Sanofi U.S.") and Sanofi Mature IP (collectively, "Plaintiffs"), by their attorneys, hereby allege as follows:

NATURE OF THE ACTION

1. This is an action for patent infringement arising under the patent laws of the United States, Title 35, United States Code and for declaratory judgment pursuant to the Declaratory Judgment Act, 28 U.S.C. §§ 2201, *et seq*. This action relates to the Abbreviated New Drug Application ("ANDA") submitted by the above-named defendant to the U.S. Food and Drug Administration ("FDA") for approval to engage in the commercial manufacture, use, or sale of cabazitaxel injection, for intravenous infusion, a generic version of Plaintiffs' JEVTANA® KIT (hereinafter "JEVTANA®"), prior to the expiration of U.S. Patent Nos. 10,583,110 ("the '110 patent") and 10,716,777 ("the '777 patent").

THE PARTIES

2. Plaintiff Sanofi U.S. is a company organized and existing under the laws of the State of Delaware, having commercial headquarters at 55 Corporate Drive, Bridgewater, New Jersey 08807.

3. Plaintiff Sanofi Mature IP is a company organized and existing under the laws of France, having its principal place of business at 54 rue La Boétie, 75008 Paris, France.

4. Plaintiffs are owned by Sanofi, a global research-driven pharmaceutical company that discovers, develops, manufactures, and markets a broad range of innovative products to improve human health.

5. On information and belief, Defendant Mylan Laboratories Limited (hereinafter "MLL") is a company organized and existing under the laws of India, having a principal place of business at Plot No. 564/A/22, Road No. 92, Jubilee Hills, Hyderabad, Telangana 500034, India.

6. On information and belief, MLL is a pharmaceutical company in the business of, among other things, developing, manufacturing and/or distributing generic drug products for marketing, sale, and/or use throughout the United States, including in this Judicial District.

7. On information and belief, MLL assembled and caused to be submitted to the FDA ANDA No. 207381 pursuant to 21 U.S.C. § 355(j) (§ 505(j) of the Federal Food, Drug and Cosmetic Act ("FDCA")) (hereinafter "the MLL ANDA") concerning a proposed drug product, Cabazitaxel Injection, 60 mg/1.5 mL (hereinafter "MLL's Proposed ANDA Product"). The MLL ANDA refers to and relies upon Sanofi U.S.'s NDA No. 201023 for JEVTANA®.

8. By a letter dated May 28, 2020 (the "Notice Letter"), MLL notified Plaintiffs that, as a part of its ANDA, MLL had filed a certification of the type described in Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), with respect to the '110 patent, which is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for JEVTANA®, asserting that the '110 patent is invalid,

unenforceable, and/or will not be infringed by the commercial manufacture, use, and sale of MLL's Proposed ANDA Product.

9. Plaintiffs filed this suit against MLL for infringement of the '110 patent on June 5, 2020, within 45 days of receiving the Notice Letter.

10. MLL answered Plaintiffs' Complaint on July 2, 2020.

11. MLL advised the Court by letter dated July 1, 2020 that the '777 patent would issue on July 21, 2020. The '777 patent issued on July 21, 2020.

12. Pursuant to 21 C.F.R. § 314.53(d)(3), Plaintiffs have timely submitted to the FDA the patent number and expiration date of the '777 patent and identified it as a patent "with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner engaged in the manufacture, use, or sale of the drug." The '777 will imminently be listed in the Orange Book for JEVTANA®.

13. On information and belief, the FDA has granted tentative approval to the MLL ANDA.

PRIOR JEVTANA® LITIGATION WITH MLL

14. By letters dated December 4, 2014 and May 5, 2015, MLL notified Plaintiffs that, as a part of its ANDA, MLL had filed certifications of the type described in Section 505(j)(2)(A)(vii)(IV) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV), with respect to U.S. Patent Nos. 5,847,170 ("the '170 patent") and 8,927,592 ("the '592 patent"), both of which were listed in the Orange Book for JEVTANA®, asserting that the '170 patent and '592 patent are invalid, unenforceable, and/or will not be infringed by the commercial manufacture, use, and/or sale of MLL's Proposed ANDA Product.

15. Plaintiffs filed suit against MLL for infringement of the '170 patent and the '592 patent within 45 days of receiving these Notice Letters. *See Sanofi-Aventis US LLC et*

al. v. Mylan Laboratories Ltd., C.A. No. 15-cv-290-MAS-LHG (D.N.J.); *Sanofi-Aventis US LLC et al. v. Mylan Laboratories Ltd.*, C.A. No. 15-cv-3392-MAS-LHG (D.N.J.).

16. The court conducted an eight-day bench trial on September 18-20 and September 25-29, 2017.

17. After trial, the court concluded that: 1) the defendants (including MLL) infringed the '170 patent; 2) the defendants failed to demonstrate the invalidity of the infringed claims of the '170 patent by clear and convincing evidence; and 3) the defendants demonstrated invalidity of the asserted claims of the '592 patent by clear and convincing evidence.

18. The court entered final judgment in favor of Plaintiffs and against MLL that the commercial manufacture, use, sale, or offer for sale within the United States or importation into the United States of the cabazitaxel injection product that is the subject of the MLL ANDA would infringe claims 1 and 2 of the '170 patent. The court ordered that pursuant to 35 U.S.C. § 271(e)(4)(A), the effective date of any final approval by the FDA of MLL's ANDA shall not be a date earlier than the expiration of the '170 patent together with the period of Pediatric Exclusivity awarded to Plaintiffs, which is currently September 26, 2021. The court also enjoined MLL pursuant to 35 U.S.C. § 271(e)(4)(B) from commercial manufacture, use, sale, or offer for sale within the United States or importation into the United States of MLL's Proposed ANDA Product until the expiration of the '170 patent, which is currently March 26, 2021.

19. On appeal, the United States Court of Appeals for the Federal Circuit affirmed the district court's judgment of nonobviousness concerning claims 1 and 2 of the '170 patent.

JURISDICTION AND VENUE

20. This action arises under the patent laws of the United States, 35 U.S.C. §§ 100, *et seq.*, and this Court has jurisdiction over the subject matter of this action under 28 U.S.C. §§ 1331 and 1338(a).

21. This Court has personal jurisdiction over MLL. On information and belief, MLL directly or through its alter ego, affiliates, or agents develops, formulates, manufactures, markets, imports, and sells pharmaceutical products, including generic drug products, throughout the United States, including in Delaware. On information and belief, MLL regularly conducts and solicits business in the State of Delaware, engages in other persistent courses of conduct in the State of Delaware, and/or derives substantial revenue from services or things used or consumed in the State of Delaware. On information and belief, MLL transacts business within the state of Delaware related to Plaintiffs' claims, and has engaged in systematic, pervasive, and continuous business contacts within the State of Delaware.

22. On information and belief, MLL maintains an agent for service of process at 874 Walker Rd STE C, Dover DE 19904.

23. On information and belief, MLL has consented to jurisdiction and venue in this District by participating in one or more prior cases arising out of the filing of its ANDAs. *See, e.g.*, *Merck Sharp & Dohme Corp. v. Mylan Laboratories Limited*, C.A. No. 18-450-MN (D. Del. Apr. 19, 2018), D.I. 7; *Teva Pharmaceuticals International GmbH et al v. Fresenius Kabi USA, LLC et al.*, C.A. No. 18-1586-CFC (D. Del. Nov. 9, 2018), D.I. 11; and *Teva Pharmaceuticals International GmbH et al v. Mylan Laboratories Limited*, C.A. No. 17-1790-CFC (D. Del. Feb. 14, 2018), D.I. 12.

24. MLL is also subject to personal jurisdiction in the State of Delaware because, by submitting and maintaining the MLL ANDA with the intent to make, use, offer to

sell, and/or sell the drug product that is subject of ANDA No. 207381 in this judicial district, MLL has committed, aided, abetted, contributed to, and/or participated in the commission of tortious acts of patent infringement under 35 U.S.C. § 271(e)(2) that have led and/or will lead to foreseeable harm and injury to Plaintiff Sanofi U.S., which is a Delaware company.

25. In the alternative, MLL is subject to jurisdiction throughout the United States, and specifically in the State of Delaware pursuant to Fed. R. Civ. P. 4(k)(2).

26. On information and belief, upon approval of the MLL ANDA, MLL and/or its subsidiaries, affiliates or agents will market, sell and/or distribute MLL's Proposed ANDA Product throughout the United States, including in this Judicial District, and will derive substantial revenue therefrom.

27. On information and belief, upon approval of the MLL ANDA, MLL and/or its subsidiaries, affiliates or agents will place MLL's Proposed ANDA Product into the stream of commerce with the reasonable expectation or knowledge and the intent that such product will ultimately be purchased and used by consumers in this Judicial District.

28. Venue is proper in this judicial district under 28 U.S.C. § 1391 because, among other things, MLL is a foreign company and is thus subject to suit in any judicial district. 28 U.S.C. § 1391(c)(3).

JEVTANA® AND THE PATENTS-IN-SUIT

29. Sanofi U.S. holds approved NDA No. 201023 for cabazitaxel injection, 60 mg/ 1.5 mL (40 mg/mL), which is prescribed and sold in the United States under the trademark JEVTANA® KIT. The FDA approved NDA No. 201023 on June 17, 2010. JEVTANA® is approved for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

30. United States Patent No. 10,583,110 (copy attached as Exhibit A) is entitled "Antitumoral Use of Cabazitaxel" and was duly and legally issued by the United States Patent and Trademark Office on March 10, 2020. It is owned by Sanofi Mature IP. The '110 patent is related to the '592 patent by a chain of continuation applications and relies on the same provisional patent applications. The '110 patent is directed to methods for increasing survival of prostate cancer patients with cabazitaxel, including the use of JEVTANA® in accordance with the labeling approved by the FDA.

31. The claims of the '110 patent are materially different from and patentably distinct from all issued claims of the '592 patent, because, among other things, the claims of the '110 patent require administration of cabazitaxel with the intentional purpose of prolonging survival and administration of a premedication regimen, neither of which was a limitation in any issued claim of the '592 patent.

32. United States Patent No. 10,716,777 (copy attached as Exhibit B) is entitled "Antitumoral Use of Cabazitaxel" and was duly and legally issued by the United States Patent and Trademark Office on July 21, 2020. It is owned by Sanofi Mature IP. The '777 patent is a continuation of the '110 patent and relies on the same provisional patent applications. The '777 patent is directed to methods for increasing survival of prostate cancer patients with cabazitaxel, including the use of JEVTANA® in accordance with the labeling approved by the FDA.

33. The claims of the '777 patent are materially different and patentably distinct from all issued claims of the '592 patent, because, among other things, the claims of the '777 patent require administration of cabazitaxel with the intentional purpose of prolonging

survival and administration of an H_2 antagonist, neither of which was a limitation in any issued claim of the ’592 patent.

COUNT I: INFRINGEMENT OF U.S. PATENT NO. 10,583,110 UNDER 35 U.S.C. § 271(e)

34. Plaintiffs incorporate each of the preceding paragraphs 1 – 33 as if fully set forth herein.

35. By submitting and maintaining the MLL ANDA under 21 U.S.C. § 355(j) for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL’s Proposed ANDA Product throughout the United States prior to expiration of the ’110 patent, MLL committed an act of infringement of one or more claims of the ’110 patent under 35 U.S.C. § 271(e)(2).

36. On information and belief, MLL intends to engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL’s Proposed ANDA Product with proposed labeling immediately and imminently upon final approval.

37. On information and belief, the proposed labeling for MLL’s Proposed ANDA Product will be substantially identical to the JEVTANA® label, and instructs and encourages physicians to practice the claimed methods of the ’110 patent.

38. The JEVTANA® label states that the indication is “treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.” (JEVTANA® label at § 1, copy attached as Exhibit C). The JEVTANA® label describes the pivotal TROPIC clinical study in which cabazitaxel was shown to prolong overall survival of these patients, and therefore instructs physicians that JEVTANA® increases

survival and encourages physicians to administer the drug to those patients for that purpose in accordance with the claimed methods of the '110 patent. (JEVTANA® label at § 14).

39. The recommended dose of cabazitaxel in the JEVTANA® label is 20 mg/m^2 administered as a one-hour intravenous infusion every three weeks. A dose of 25 mg/m^2 "can be used in select patients." Patients at 20 mg/m^2 who require dose reduction should receive 15 mg/m^2, and patients at 25 mg/m^2 who require dose reduction should receive 20 mg/m^2. (JEVTANA® label at § 2). The JEVTANA® label therefore instructs and encourages physicians to administer 15 mg/m^2, 20 mg/m^2, or 25 mg/m^2 of cabazitaxel in accordance with the claimed methods of the '110 patent.

40. The JEVTANA® label instructs physicians to "[p]remedicate at least 30 minutes prior to each dose of JEVTANA® with the following intravenous medications to reduce the risk and/or severity of hypersensitivity: antihistamine (dexchlorpheniramine 5 mg, or diphenhydramine 25 mg or equivalent antihistamine), corticosteroid (dexamethasone 8 mg or equivalent steroid), H_2 antagonist (ranitidine 50 mg or equivalent H_2 antagonist)." (JEVTANA® label at § 2.1). The JEVTANA® label therefore instructs and encourages physicians to administer the premedications recited in the '110 patent claims in accordance with the claimed methods of the '110 patent.

41. Thus, on information and belief, the use of MLL's Proposed ANDA Product in accordance with its proposed labeling will directly infringe at least one claim of the '110 patent under 35 U.S.C. § 271(a).

42. In the Notice Letter, MLL has not contested the infringement of any claim of the '110 patent.

43. On information and belief, MLL has actual knowledge of the '110 patent and will actively induce direct infringement of at least one claim of the '110 patent under 35 U.S.C. § 271(b) when MLL's ANDA is approved and MLL's Proposed ANDA Product is marketed, sold, distributed, and/or imported.

44. The foregoing acts by MLL constitute and/or will constitute infringement of the '110 patent and/or active inducement of infringement of the '110 patent under 35 U.S.C. § 271(b).

45. If MLL's infringement of the '110 patent is not permanently enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no remedy at law.

COUNT II: DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 10,583,110 UNDER 35 U.S.C. § 271(B)

46. Plaintiffs incorporate each of the preceding paragraphs 1 – 45 as if fully set forth herein.

47. On information and belief, MLL intends to engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL's Proposed ANDA Product with proposed labeling immediately and imminently upon final approval and prior to the expiration of the '110 patent. Therefore, a case or controversy exists between MLL and Plaintiffs as to infringement of the '110 patent.

48. The commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL's Proposed ANDA Product would infringe one or more claims of the '110 patent.

49. On information and belief, the proposed labeling for MLL's Proposed ANDA Product's will be substantially identical to the JEVTANA® label, and instructs and encourages physicians to practice the claimed methods of the '110 patent.

50. The JEVTANA® label states that the indication is "treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen." (JEVTANA® label at § 1). The JEVTANA® label describes the pivotal TROPIC clinical study in which cabazitaxel was shown to prolong overall survival of these patients, and therefore instructs physicians that JEVTANA® increases survival and encourages physicians to administer the drug to those patients for that purpose in accordance with the claimed methods of the '110 patent. (JEVTANA® label at § 14).

51. The recommended dose of cabazitaxel in the JEVTANA® label is 20 mg/m^2 administered as a one-hour intravenous infusion every three weeks. A dose of 25 mg/m^2 "can be used in select patients." Patients at 20 mg/m^2 who require dose reduction should receive 15 mg/m^2, and patients at 25 mg/m^2 who require dose reduction should receive 20 mg/m^2. (JEVTANA® label at § 2). The JEVTANA® label therefore instructs and encourages physicians to administer 15 mg/m^2, 20 mg/m^2, or 25 mg/m^2 of cabazitaxel in accordance with the claimed methods of the '110 patent.

52. The JEVTANA® label instructs physicians to "[p]remedicate at least 30 minutes prior to each dose of JEVTANA® with the following intravenous medications to reduce the risk and/or severity of hypersensitivity: antihistamine (dexchlorpheniramine 5 mg, or diphenhydramine 25 mg or equivalent antihistamine), corticosteroid (dexamethasone 8 mg or equivalent steroid), H_2 antagonist (ranitidine 50 mg or equivalent H_2 antagonist)." (JEVTANA® label at § 2.1). The JEVTANA® label therefore instructs and encourages physicians to administer the premedications recited in the '110 patent claims in accordance with the claimed methods of the '110 patent.

53. Thus, on information and belief, the use of MLL's Proposed ANDA Product in accordance with its proposed labeling will directly infringe at least one claim of the '110 patent under 35 U.S.C. § 271(a).

54. In the Notice Letter, MLL has not contested the infringement of any claim of the '110 patent.

55. On information and belief, MLL has actual knowledge of the '110 patent and will actively induce direct infringement of at least one claim of the '110 patent under 35 U.S.C. § 271(b) when the MLL ANDA is approved and MLL's Proposed ANDA Product is marketed, sold, distributed, and/or imported.

56. The foregoing acts by MLL constitute and/or will constitute active inducement of infringement of the '110 patent under 35 U.S.C. § 271(b).

57. If MLL's infringement of the '110 patent is not permanently enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no remedy at law.

COUNT III: INFRINGEMENT OF U.S. PATENT NO. 10,716,777 UNDER 35 U.S.C. § 271(e)

58. Plaintiffs incorporate each of the preceding paragraphs 1 – 57 as if fully set forth herein.

59. By submitting and maintaining the MLL ANDA under 21 U.S.C. § 355(j) for the purpose of obtaining approval to engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL's Proposed ANDA Product throughout the United States prior to expiration of the '777 patent, MLL committed an act of infringement of one or more claims of the '777 patent under 35 U.S.C. § 271(e)(2).

60. On information and belief, MLL intends to engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL's

Proposed ANDA Product with proposed labeling immediately and imminently upon final approval.

61. On information and belief, the proposed labeling for MLL's Proposed ANDA Product will be substantially identical to the JEVTANA® label, and instructs and encourages physicians to practice the claimed methods of the '777 patent.

62. The JEVTANA® label states that the indication is "treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen." (JEVTANA® label at § 1). The JEVTANA® label describes the pivotal TROPIC clinical study in which cabazitaxel was shown to prolong overall survival of these patients, and therefore instructs physicians that JEVTANA® increases survival and encourages physicians to administer the drug to those patients for that purpose in accordance with the claimed methods of the '777 patent. (JEVTANA® label at § 14).

63. The recommended dose of cabazitaxel in the JEVTANA® label is 20 mg/m^2 administered as a one-hour intravenous infusion every three weeks. A dose of 25 mg/m^2 "can be used in select patients." Patients at 25 mg/m^2 who require dose reduction should receive 20 mg/m^2. (JEVTANA® label at § 2). The JEVTANA® label therefore instructs and encourages physicians to administer 20 mg/m^2 or 25 mg/m^2 of cabazitaxel in accordance with the claimed methods of the '777 patent.

64. The JEVTANA® label instructs physicians to "[p]remedicate at least 30 minutes prior to each dose of JEVTANA® with the following intravenous medications to reduce the risk and/or severity of hypersensitivity: antihistamine (dexchlorpheniramine 5 mg, or diphenhydramine 25 mg or equivalent antihistamine), corticosteroid (dexamethasone 8 mg or equivalent steroid), H_2 antagonist (ranitidine 50 mg or equivalent H_2 antagonist)." (JEVTANA®

label at § 2.1). The JEVTANA® label therefore instructs and encourages physicians to administer the H_2 antagonist recited in the '777 patent claims in accordance with the claimed methods of the '777 patent.

65. Thus, on information and belief, the use of MLL's Proposed ANDA Product in accordance with its proposed labeling will directly infringe at least one claim of the '777 patent under 35 U.S.C. § 271(a).

66. On information and belief, MLL has actual knowledge of the '777 patent and will actively induce direct infringement of at least one claim of the '777 patent under 35 U.S.C. § 271(b) when MLL's ANDA is approved and MLL's Proposed ANDA Product is marketed, sold, distributed, and/or imported.

67. The foregoing acts by MLL constitute and/or will constitute infringement of the '777 patent and/or active inducement of infringement of the '777 patent under 35 U.S.C. § 271(b).

68. If MLL's infringement of the '777 patent is not permanently enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no remedy at law.

COUNT IV: DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 10,716,777 UNDER 35 U.S.C. § 271(B)

69. Plaintiffs incorporate each of the preceding paragraphs 1 – 68 as if fully set forth herein.

70. On information and belief, MLL intends to engage in the commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL's Proposed ANDA Product with proposed labeling immediately and imminently upon final approval and prior to the expiration of the '777 patent. Therefore, a case or controversy exists between MLL and Plaintiffs as to infringement of the '777 patent.

71. The commercial manufacture, use, offer for sale, sale, marketing, distribution, and/or importation of MLL's Proposed ANDA Product would infringe one or more claims of the '777 patent.

72. On information and belief, the proposed labeling for MLL's Proposed ANDA Product's will be substantially identical to the JEVTANA® label, and instructs and encourages physicians to practice the claimed methods of the '777 patent.

73. The JEVTANA® label states that the indication is "treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen." (JEVTANA® label at § 1). The JEVTANA® label describes the pivotal TROPIC clinical study in which cabazitaxel was shown to prolong overall survival of these patients, and therefore instructs physicians that JEVTANA® increases survival and encourages physicians to administer the drug to those patients for that purpose in accordance with the claimed methods of the '777 patent. (JEVTANA® label at § 14).

74. The recommended dose of cabazitaxel in the JEVTANA® label is 20 mg/m^2 administered as a one-hour intravenous infusion every three weeks. A dose of 25 mg/m^2 "can be used in select patients." Patients at 25 mg/m^2 who require dose reduction should receive 20 mg/m^2. (JEVTANA® label at § 2). The JEVTANA® label therefore instructs and encourages physicians to administer 20 mg/m^2 or 25 mg/m^2 of cabazitaxel in accordance with the claimed methods of the '777 patent.

75. The JEVTANA® label instructs physicians to "[p]remedicate at least 30 minutes prior to each dose of JEVTANA® with the following intravenous medications to reduce the risk and/or severity of hypersensitivity: antihistamine (dexchlorpheniramine 5 mg, or diphenhydramine 25 mg or equivalent antihistamine), corticosteroid (dexamethasone 8 mg or

equivalent steroid), H_2 antagonist (ranitidine 50 mg or equivalent H_2 antagonist)." (JEVTANA® label at § 2.1). The JEVTANA® label therefore instructs and encourages physicians to administer the H_2 antagonist recited in the '777 patent claims in accordance with the claimed methods of the '777 patent.

76. Thus, on information and belief, the use of MLL's Proposed ANDA Product in accordance with its proposed labeling will directly infringe at least one claim of the '777 patent under 35 U.S.C. § 271(a).

77. On information and belief, MLL has actual knowledge of the '777 patent and will actively induce direct infringement of at least one claim of the '777 patent under 35 U.S.C. § 271(b) when the MLL ANDA is approved and MLL's Proposed ANDA Product is marketed, sold, distributed, and/or imported.

78. The foregoing acts by MLL constitute and/or will constitute active inducement of infringement of the '777 patent under 35 U.S.C. § 271(b).

79. If MLL's infringement of the '777 patent is not permanently enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no remedy at law.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request the following relief:

A. A judgment that MLL's submission and maintenance of its ANDA constituted an act of infringement of the '110 patent;

B. A judgment (or a declaration) that MLL's making, using, offering to sell, or selling in the United States or importing into the United States of MLL's Proposed ANDA Product will infringe the '110 patent;

C. A permanent injunction restraining and enjoining MLL, its affiliates, subsidiaries, and each of their officers, agents, attorneys and employees, and those acting in

privity or concert with them, from engaging in the commercial manufacture, use, offer for sale, or sale within the United States, or importation into the United States, of MLL's Proposed ANDA Product until the expiration of the '110 patent, including any extensions and/or periods of exclusivity to which Plaintiffs and/or the '110 patent are or become entitled;

D. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any approval of MLL's ANDA shall be a date that is not earlier than the expiration date of the '110 patent, including any extensions and/or periods of exclusivity to which Plaintiffs and/or the '110 patent are or become entitled;

E. A judgment that MLL's submission and maintenance of its ANDA constituted an act of infringement of the '777 patent;

F. A judgment (or a declaration) that MLL's making, using, offering to sell, or selling in the United States or importing into the United States of MLL's Proposed ANDA Product will infringe the '777 patent;

G. A permanent injunction restraining and enjoining MLL, its affiliates, subsidiaries, and each of their officers, agents, attorneys and employees, and those acting in privity or concert with them, from engaging in the commercial manufacture, use, offer for sale, or sale within the United States, or importation into the United States, of MLL's Proposed ANDA Product until the expiration of the '777 patent, including any extensions and/or periods of exclusivity to which Plaintiffs and/or the '777 patent are or become entitled;

H. An order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of any approval of MLL's ANDA shall be a date that is not earlier than the expiration date of the '777 patent, including any extensions and/or periods of exclusivity to which Plaintiffs and/or the '777 patent are or become entitled;

I. Damages, including monetary and other relief, to Plaintiffs if MLL engages in commercial manufacture, use, offers to sell, sale, or importation in or into the United States of MLL's Proposed ANDA Product, prior to the expiration date of the '110 patent and/or the '777 patent, including any extensions and/or additional periods of exclusivity to which Plaintiffs are or become entitled;

J. A declaration that this case is "exceptional" within the meaning of 35 U.S.C. § 285 and an award of reasonable attorney fees, costs, expenses, and disbursements of this action; and

K. Such other and further relief as the Court may deem just and proper.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Jack B. Blumenfeld

Jack B. Blumenfeld (#1014)
Derek J. Fahnestock (#4705)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@mnat.com
dfahnestock@mnat.com

Attorneys for Sanofi-Aventis U.S. LLC and Sanofi Mature IP

OF COUNSEL:

William E. Solander
Daniel J. Minion
Whitney L. Meier
VENABLE LLP
1270 Avenue of the Americas
New York, NY 10020
(212) 218-2100

Michael S. Scerbo
VENABLE LLP
1290 Avenue of the Americas
New York, NY 10104
(212) 218-2100

July 22, 2020

CERTIFICATE OF SERVICE

I hereby certify that on July 22, 2020, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on July 22, 2020, upon the following in the manner indicated:

David E. Moore, Esquire — *VIA ELECTRONIC MAIL*
Bindu A. Palapura, Esquire
Tracey E. Timlin, Esquire
POTTER ANDERSON & CORROON LLP
Hercules Plaza, 6th Floor
1313 North Market Street
Wilmington, DE 19801
Attorneys for Defendant Mylan Laboratories Limited

Wendy Lynn Devine, Esquire — *VIA ELECTRONIC MAIL*
Kristina M. Hanson, Esquire
WILSON SONSINI GOODRICH AND ROSATI
One Market Plaza
Spear Tower, Suite 3300
San Francisco, CA 94105
Attorneys for Defendant Mylan Laboratories Limited

Matthew R. Reed, Esquire — *VIA ELECTRONIC MAIL*
G. Edward Powell, III, Esquire
WILSON SONSINI GOODRICH AND ROSATI
650 Page Mill Road
Palo Alto, CA 94304
Attorneys for Defendant Mylan Laboratories Limited

/s/ Jack B. Blumenfeld
Jack B. Blumenfeld (#1014)